Market Place
Sourcing Support
Connect Biopharma To Participate In Cantor Conference
10 Sep 2024 //
GLOBENEWSWIRE
Connect Biopharma Reports First Half 2024 Financial Results
05 Sep 2024 //
GLOBENEWSWIRE
Connect Biopharma To Join Leerink Partners I&I Forum
01 Jul 2024 //
GLOBENEWSWIRE
Connect Biopharma Announces New Leadership and Chair of the Board of Directors
12 Jun 2024 //
GLOBENEWSWIRE
Connect Biopharma Announces Inducement Grants Under Nasdaq Rules
12 Jun 2024 //
GLOBENEWSWIRE
Connect Bio Presents Positive Rademikibart Phase 2b Asthma At ATS
22 May 2024 //
GLOBENEWSWIRE
Connect Biopharma Asthma Data At ATS 2024
07 May 2024 //
GLOBENEWSWIRE
Connect uncouples from Pfizer by scrapping eczema pact
17 Apr 2024 //
FIERCE BIOTECH
Connect Biopharma Reports 2023 Financials, Provides Business Update
16 Apr 2024 //
GLOBENEWSWIRE
Connect Biopharma to Participate in Virtual Conference
19 Mar 2024 //
GLOBENEWSWIRE
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
13 Feb 2024 //
GLOBENEWSWIRE
Connect Biopharma Appoints Industry Veteran James Huang to Board of Directors
12 Feb 2024 //
GLOBENEWSWIRE
Rigel Announces Collaboration with CONNECT to Conduct Phase 2 of Olutasidenib
04 Jan 2024 //
PR NEWSWIRE
Connect Bio Announces Positive Rademikibart Global Phase 2b Topline Results
12 Dec 2023 //
GLOBENEWSWIRE
Connecting the dots: Asthma asset aces phase 2b trial
12 Dec 2023 //
FIERCE BIOTECH
Connect Biopharma to Announce Top-Line Data from Phase 2b Trial of Rademikibart
11 Dec 2023 //
GLOBENEWSWIRE
Connect Biopharma Announces Data from the China Pivotal Trial of Rademikibart
21 Nov 2023 //
GLOBENEWSWIRE
Connect Biopharma and Simcere Announce Agreement in Greater China
21 Nov 2023 //
GLOBENEWSWIRE
Connect Biopharma to Announce Data from the China Pivotal Trial of Rademikibart
20 Nov 2023 //
GLOBENEWSWIRE
Connect Biopharma Reports First Half 2023 Financial Results
12 Sep 2023 //
GLOBENEWSWIRE
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice
12 Sep 2023 //
GLOBENEWSWIRE
Connect Biopharma to Participate in Upcoming September Investor Conferences
24 Aug 2023 //
GLOBENEWSWIRE
Connect Bio Presented Additional Data from its Atopic Dermatitis Pivotal Trial
10 Jul 2023 //
GLOBENEWSWIRE
Connect Biopharma to Participate in the SVB Securities Therapeutics Forum
05 Jul 2023 //
GLOBENEWSWIRE
Connect Biopharma Announces Positive Data from Icanbelimod Trial
01 Jun 2023 //
GLOBENEWSWIRE
Connect Reports Full Year 2022 Financial Results and Provides Business Update
11 Apr 2023 //
GLOBENEWSWIRE
Connect Biopharma CBP-201 Study Showed Rapid Relief of Patient Symptoms
18 Mar 2023 //
BUSINESSWIRE
Connect CBP-201 Atopic Dermatitis Ph2b Showed Improvement Across Body Regions
17 Mar 2023 //
BUSINESSWIRE
Connect CBP-201 Atopic Dermatitis Abstracts from Two Trials Accepted
06 Mar 2023 //
BUSINESSWIRE
Connect Biopharma to Present at SVB Securities Global Biopharma Conference
06 Feb 2023 //
GLOBENEWSWIRE
Connect Biopharma Provides Business and Clinical Development Program Update
30 Dec 2022 //
GLOBENEWSWIRE
Connect Biopharma to Present at the San Francisco Biotech Showcase in January
19 Dec 2022 //
GLOBENEWSWIRE
Connect Biopharma To Present at Upcoming Investor and Scientific Conferences
27 Oct 2022 //
GLOBENEWSWIRE
Connect Biopharma Reports CBP-201 Achieved All Primary & Key Secondary Endpoints
04 Oct 2022 //
GLOBENEWSWIRE
Connect Biopharma Reports CBP-201 Achieved All Primary & Key Secondary Endpoints
04 Oct 2022 //
GLOBENEWSWIRE
Connect Biopharma to Host a Conference Call, Oct 4 to Discuss Topline Results
03 Oct 2022 //
GLOBENEWSWIRE
Connect Biopharma Reports First Half 2022 Financial Results a
13 Sep 2022 //
GLOBENEWSWIRE
Connect Biopharma to Report First Half 2022 Financial Results on September 13
01 Sep 2022 //
GLOBENEWSWIRE
Connect BioPharma Successfully Completes CBP-174 Phase 1 Single Ascending Dose
30 Aug 2022 //
GLOBENEWSWIRE
Connect Biopharma Announces Receipt of NASDAQ Deficiency Notice
17 Jun 2022 //
GLOBENEWSWIRE
Connect Biopharma to Participate at the Jefferies Healthcare Conference
02 Jun 2022 //
GLOBENEWSWIRE
Connect Biopharma Presents CBP-201 Target Engagement and Immune Modulation Data
17 May 2022 //
GLOBENEWSWIRE
Chasing BMS and Pfizer, Connect fails ulcerative colitis trial
05 May 2022 //
FIERCEBIOTECH
Connect Biopharma reports a PII fail for Zeposia challenger
04 May 2022 //
ENDPTS
Connect Biopharma Announces Week 12 Top-Line Results from Phase 2 CBP-307 Trial
03 May 2022 //
GLOBENEWSWIRE
Connect Biopharma Reports Full Year 2021 Financial Results
31 Mar 2022 //
GLOBENEWSWIRE
Connect Biopharma Appoints Chin Lee, MD, MPH as Chief Medical Officer
01 Mar 2022 //
GLOBENEWSWIRE
Connect Biopharma Expands Executive Leadership Team with Hire
22 Nov 2021 //
GLOBENEWSWIRE
Connect Bio celebrates mid-stage win for Dupixent rival, but shares tank
20 Nov 2021 //
ENDPTS
Connect Biopharma Completes Enrollment of CBP-307 Global Phase 2 Clinical Trial
19 Nov 2021 //
GLOBENEWSWIRE
Connect Reports +ve Top-Line Results from the Global P2 Trial of CBP-201
18 Nov 2021 //
GLOBENEWSWIRE
Connect Biopharma to Participate at the Jefferies Virtual China Biotech Summit
19 Oct 2021 //
GLOBENEWSWIRE
Connect Biopharma doses First Subject in PII Trial of CBP-201 in Adult Patients
08 Sep 2021 //
GLOBENEWSWIRE
Connect Biopharma Provides Business Update and Reports First Half 2021 Results
31 Aug 2021 //
GLOBENEWSWIRE
Connect Biopharma Hires General Counsel & CCO and Appoints a New Board Member
23 Aug 2021 //
GLOBENEWSWIRE
Connect Biopharma Announces First Subject Dosed in Phase I Trial
25 May 2021 //
GLOBENEWSWIRE
Connect Biopharma Completes Enrollment of CBP-201 Global Phase 2
08 Apr 2021 //
GLOBENEWSWIRE
Connect Biopharma Holdings Limited Announces Closing of Initial Public Offering
23 Mar 2021 //
GLOBENEWSWIRE
Three drugmakers nab $639M as biotech`s IPO pace eclipses a record year
20 Mar 2021 //
BIOPHARMADIVE
Complete Data from Connect Biopharma`s Phase 1b Study of CBP-201
29 Oct 2020 //
PRNEWSWIRE
